Fox Run Management L.L.C. Has $352,000 Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)

Fox Run Management L.L.C. lifted its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 261.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,213 shares of the company’s stock after purchasing an additional 16,069 shares during the quarter. Fox Run Management L.L.C.’s holdings in Keros Therapeutics were worth $352,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of KROS. KLP Kapitalforvaltning AS bought a new stake in Keros Therapeutics in the fourth quarter worth $90,000. American Century Companies Inc. lifted its position in shares of Keros Therapeutics by 10.5% in the fourth quarter. American Century Companies Inc. now owns 328,920 shares of the company’s stock worth $5,207,000 after buying an additional 31,251 shares during the last quarter. Swiss National Bank boosted its stake in shares of Keros Therapeutics by 4.8% during the 4th quarter. Swiss National Bank now owns 59,000 shares of the company’s stock worth $934,000 after acquiring an additional 2,700 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Keros Therapeutics during the 4th quarter valued at about $461,000. Finally, AlphaQuest LLC increased its holdings in shares of Keros Therapeutics by 469.0% during the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock valued at $57,000 after acquiring an additional 2,964 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Trading Down 2.5 %

KROS opened at $11.01 on Thursday. The stock’s 50 day simple moving average is $11.14 and its 200-day simple moving average is $35.05. The stock has a market cap of $446.59 million, a PE ratio of -2.11 and a beta of 1.39. Keros Therapeutics, Inc. has a 1 year low of $9.78 and a 1 year high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.36) by $0.22. The firm had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Equities analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Truist Financial decreased their target price on Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a research report on Monday, December 23rd. Wells Fargo & Company decreased their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. TD Cowen lowered shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Oppenheimer lowered their price target on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a research report on Thursday, January 16th. Finally, Piper Sandler cut their price objective on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a research report on Friday, January 17th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Keros Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $42.33.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.